Abstract. The aim of this report is to review and evaluate, in a comprehensive manner, the published data regarding the contribution of genetic polymorphisms to risk of head and neck cancer (HNC). All relevant studies available in MEDLINE and published before July 2007 were identified. Studies carried out in humans that compared HNC patients with at least 1 standard control group were considered for analysis. Two hundred and eighteen publications and 3 published metaanalyses were identified. Seventy-five (34%) studies were conducted in Asian, 72 (33%) in American, and 68 (31%) in European countries. The most widely studied gene was GSTM1 (58 studies), followed by GSTT1 (42 studies), GSTP1 (codon 105, 22 studies) and p53 (codon 72, 20 studies). GSTM1, GSTT1, GSTP1, XRCC1 codons 194 and 399, and CYP1A1 codon 462 were examined by meta-analyses, and significant relations were found between the GSTM1-null genotype and an increased risk for HNC. In addition, increased risk for HNC was associated consistently with the ALDH2*1/*2, p53 codon 72 Pro/Pro and EPHX1 codon 113 Tyr/His and His/His genotypes. Cohort studies that simultaneously consider multiple genetic and environmental factors possibly involved in carcinogenesis of the head and neck are needed to ascertain not only the relative contribution of these factors to tumor development but also the contributions of their putative interactions. 
Introduction
Head and neck cancers (HNCs), including cancers of the oral cavity, pharynx and larynx, represent the 6 most frequent cancers and the seventh leading cause of cancer-related death worldwide. There are approximately 540,000 new cases and 271,000 deaths annually worldwide for a mortality of approximately 50% (1) . HNCs represent approximately 3% of all cancers in the United States whereas these cancers are much more prevalent in other areas of the world, such as India, Thailand and Brazil (1, 2) . Standard therapeutic approaches, which focus on surgery, irradiation and chemotherapy (alone or in combination), have been modified over the last 30 years; however, the overall survival of HNC patients has not improved substantially. For patients affected by early-stage cancers with a high disease-specific survival rate, secondary tumors represent the most common cause of death (3) . Furthermore, patients with advanced cancers have a high risk of primary treatment failure and death.
Development of HNC is a multifactorial process associated with a variety of risk factors. Major risk factors in developed countries include smoking tobacco and drinking alcohol, and chewing betel quid (4, 5) . For tobacco smoking, a dose-response trend has been reported. Relative risks of developing laryngeal and oropharyngeal cancers are 1.8 and 1.3, respectively, for persons who smoke ≤30 cigarettes per day and 7.7 and 2.9, respectively, for persons who smoke >30 cigarettes per day compared with non-smokers (6) . Alcohol consumption is also linked to increased risk of HNCs. For persons who consume >4 drinks (=47.5 g of pure ethanol) per day, the relative risks of developing laryngeal and oropharyngeal cancers are 4.5 and 7.2, respectively, compared with nondrinkers (6) . A synergistic effect was observed in persons who both smoke tobacco and drink alcohol. The relative risks of developing laryngeal and oropharyngeal cancers are 34.6 and 21.2, respectively, among those who smoke >30 cigarettes a day and consume >4 drinks per week.
Genetic factors as well as environmental factors play a role in development of HNC and of other cancers (7) (8) (9) (10) (11) (12) (13) . Individual variations in cancer risk have been associated with specific variant alleles of different genes that are present in a significant proportion of the normal population. Recent studies have suggested that genetic polymorphisms may underlie some of the causes and events involved in carcinogenesis of the head and neck. A variety of genes may be associated with carcinogenesis, including genes involved in carcinogen CYP1A1. CYP1A1 is involved in the activation of major classes of tobacco procarcinogens, such as polyaromatic hydrocarbons and aromatic amines, and is present in many epithelial tissues (236) . An Ile-Val substitution in codon 462 of CYP1A1, which is in the heme-binding region, results in a 2-fold increase in microsomal enzyme activity and, in Caucasians, is in complete linkage disequilibrium with the CYP1A1 MspI polymorphism, which is also associated with increased catalytic activity (7) .
We identified 15 studies (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) with data regarding the relation of the CYP1A1 Ile-Val substitution at codon 462 to HNC. In 4 studies (14, 19, 22, 24) , the risk for HNC in subjects with the Ile/Val and/or Val/Val genotypes was significantly higher than that for subjects with the Ile/Ile genotype, suggesting that the Val allele may be associated with increased risk for HNC. A meta-analysis of studies that examined the association of the CYP1A1 Ile-Val substitution with risk for HNC revealed that the Ile/Val and Val/Val genotypes tend to increase HNC risk with odds ratios (ORs) [95% confidence interval (CI)] compared with Ile/Ile of 1.32 (0.95-1.82) (232) .
CYP2E1. CYP2E1 is primarily responsible for the metabolic activation of many low molecular weight carcinogens, including certain nitrosoamines, which may be involved in carcinogenesis of the esophagus (237, 238) . This enzyme is also believed to participate in the oxidation of other compounds, such as ethanol, to produce reactive free radicals that may initiate lipid peroxidation and consequently influence carcinogenesis (133) . The variant c2 allele, which contains a novel RsaI/PstI site in the 5'-flanking region of the CYP2E1 gene, appears to be associated with decreased enzyme activity.
Ten (15, 17, 18, 27, 28, 35, 40, 43, 46) of the 15 (67%) studies (15, 17, 18, 27, 28, 35, (39) (40) (41) (42) (43) (44) 46, 47) suggested that the c1/c2 genotype of CYP2E1 may increase risk for HNC compared with the c1/c1 genotype. Results of 6 (18, 28, (39) (40) (41) 44 ) of 7 (86%) studies (17, 18, 28, (39) (40) (41) 44) suggested that the c2/c2 genotype may increase risk for HNC.
GSTs. GSTs are a family of multifunctional enzymes that metabolize a variety of xenobiotics with a large overlap in substrate specificity (239, 240) . Individuals who are homozygous for the null GSTM1 or null GSTT1 alleles lack the respective enzyme function. The null GSTM1 genotype appears to be common in both Asians and Caucasians, whereas the frequency of the null GSTT1 genotype varies among ethnicities. The null genotypes of GSTM1 and GSTT1 appear to be associated with increased risk of esophageal (235) , gastric (241) and lung (242) cancers.
For HNCs, 36 (62%) ORs from 58 studies of the null GSTM1 genotype vs. the positive genotype were >1, suggesting that the null GSTM1 genotype may be associated with increased risk for HNC. Sixteen (28%) (30, 35, 55, 58, 62, 64, (66) (67) (68) 71, 72, 74, 79, (84) (85) (86) of the studies showed a significantly higher risk for HNC in subjects with the null GSTM1 genotype than in subjects with the positive genotype. No studies showed a significantly lower risk in patients with the null GSTM1 genotype than in those with the positive genotype. Two meta-analyses (232, 233) of studies that examined the association of GSTM1 with risk for HNC revealed that the null genotype significantly increases the risk with ORs (95% CI) of 1.23 (1.06-1.42) and 1.50 (1.21-1.87) compared with the positive genotype.
Twenty-three (55%) ORs from 42 studies of the null GSTT1 genotype vs. the positive genotype were >1, and 7 studies (56, 64, 72, 83, 85, 95, 96) showed a significantly higher risk for HNC in subjects with the null genotype than in those with the positive genotype, suggesting that the null GSTT1 genotype may be associated with increased risk for HNC. In contrast, only 1 study showed a significantly lower risk with the null GSTT1 genotype than the positive genotype. A metaanalysis (232) of studies that examined the association of GSTT1 with risk of HNC revealed that the null genotype tends to increase HNC risk with ORs (95% CI) of 1.17 (0.98-1.40) compared with positive genotype.
GSTP1 is a major GST isoform that eliminates thymidine and uracil propenal, products of DNA oxidation (243, 244) . An Ile to Val substitution at codon 105 (exon 5) has been identified. The 105Val form shows altered affinity and enzymatic activity for some substrates. Four (18%) (77, (88) (89) (90) of the 22 studies (18, 20, 21, 25, 31, 33, 63, 69, 73, 77, 80, 82, 84, (87) (88) (89) (90) (91) (92) (93) (94) NATs. Two NAT isozymes, NAT1 and NAT2, are polymorphic and catalyze both O-acetylation (activation) and N-acetylation (usually detoxification) of aromatic and heterocyclic amine carcinogens. Molecular epidemiologic studies suggest that genetic polymorphisms in NAT1 and NAT2 modify risk of developing certain cancers (245) . For HNC, all 7 (100%) ORs (18, 23, 33, 42, 97, 100, 101) for the slow NAT2 genotype vs. the rapid genotype were >1, suggesting that the slow NAT2 genotype may be associated with an increased risk for HNC.
EPHX1.
The human microsomal epoxide hydrase (mEH), which is encoded by EPHX1, cleaves a range of alkene and arene oxides to form trans-dihydrodiols. For some polycyclic aromatic hydrocarbons, including benzo[a]pyrene, dihydrodiol derivatives are substrates for additional metabolic reactions that produce more highly reactive and carcinogenic compounds. Two amino acid-altering polymorphisms, Tyr113His and His139Arg, have been identified in EPHX1 and both are associated with alterations in mEH activity. The EPHX1 His113 variant shows a 40% decrease in EH activity, whereas the EPHX1 Arg139 variant shows 25% increased enzyme activity (246) . These polymorphic alleles have been linked to increases in risk for lung (247) , colon (248) (Table II) . Alcohol consumption is classified as a risk factor for HNC according to data from epidemiologic studies (6) . Alcohol intake increases exposure to high levels of acetaldehyde, the principal metabolite of alcohol, which increases risk of cancers such as HNC. Acetoaldehyde is produced mainly from ethanol via oxidation by alcohol dehydrogenase (ADH) and is subsequently detoxified into acetate by aldehyde dehydrogenase (ALDH)-2.
Alcohol metabolic enzymes
ALDH2. ALDH2 is a polymorphic gene, and an individual's genotype at this locus determines blood acetaldehyde concentrations after drinking. A single point alteration in ALDH2 results in the ALDH2*2 allele. The protein encoded by ALDH2*2 has a Glu to Lys substitution at residue 487, resulting in an inactive subunit and the inability to metabolize acetaldehyde. The ALDH2*2 allele is rare in Western populations but prevalent in East Asian populations including Chinese, Korean, Thai, and Japanese populations (250,251) ALDH2*2/*2 homozygotes have serum acetaldehyde levels that are 13 times higher and heterozygotes have levels 4 times higher than those in *1*1 homozygotes (252) . ALDH2*2/*2 homozygotes are characterized by a facial flushing response after alcohol consumption with nausea, drowsiness, headache and other unpleasant symptoms.
Six studies (17, 66, (117) (118) (119) (120) reported a relation between ALDH2 polymorphisms and risk for HNC, and all were conducted in Japanese populations. Four (67%) studies (66, 117, 118, 120) showed a significantly increased risk for HNC in *1/*2 heterozygotes compared with *1/*1 homozygotes. In contrast, 1 (119) of 2 (50%) studies (17, 119) showed a lower risk for HNC in *2/*2 homozygotes than in *1/*1 homozygotes.
ADH3
. ADH isoenzymes, which are primarily involved in ethanol oxidation, consist of subunits encoded by ADH2 and ADH3. In contrast to ADH2, ADH3 is highly polymorphic in Caucasians. Of the 2 allelic variants, the ADH3*1 allele is associated with higher enzyme activity than the ADH3*2 allele and occurs in Caucasians at frequencies of 55-63% (253) .
In 5 (43,58,111-113) of 8 (63%) studies (43, 58, (111) (112) (113) (114) (115) (116) , ADH3*2/*1 heterozygotes showed decreased risk for HNC compared with *2/*2 homozygotes. However, in 6 (43,58, Table I . Studies on polymorphisms of carcinogen metabolic enzymes and risk of head and neck cancer. Table I . Continued. Table I . Continued. Table I . Continued. Table I . Continued. Table I . Continued. Table I . Continued. -
Cell-cycle control genes (Table IV) p53. The p53 tumor suppressor gene is frequently mutated in various human cancers including HNC (259) (260) (261) (262) . A G-to-C polymorphism in codon 72 of exon 4 results in an Arg-to-Pro substitution. Although both variants are morphologically wild-type, the Pro/Pro genotype is less effective in suppressing cellular transformation (263 Others (Table V-IX) . Relations between polymorphisms in other genes, such as folate metabolic and extracellular degra- Table II . Studies on polymorphisms of alcohol metabolic enzymes and risk of head and neck cancer. - Table III . Studies on polymorphisms of DNA repair genes and risk of head and neck cancer.
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a OC, oral cavity; P, pharynx; L, larynx; NC, not specified, b OR, odds ratio; 95% CI, 95% confidence interval; c OR and 95% CI were calculated from the genotype distribution.
- Table IV . Studies on polymorphisms of cell-cycle control genes and risk of head and neck cancer.
- Table IV . Continued. 
----------------------------------------------------------------------------------------------------
OC, oral cavity; P, pharynx; L, larynx; O, other; NC, not specified. b dup, duplication; wt, wild-type; vt, variant-type. c OR, odds ratio; 95% CI, 95% confidence interval. d OR and 95% CI were calculated from the genotype distribution.
- ---------------------------------------------------------------------------------------------------- dation enzymes, apoptosis signaling and immune response factors, have been investigated. However, the number of studies was limited, and we found it difficult to draw conclusions.
Discussion
Molecular epidemiologic studies have provided evidence that individual susceptibility to cancer is mediated by both genetic and environmental factors. Interest in the role of genetic polymorphisms in HNC has increased recently, possibly due to advances in DNA analysis technologies or our knowledge of the human genome. The most intensively studied genes are those encoding enzymes that metabolize carcinogens and include GSTM1, GSTT1 and GSTP1. This is likely because these variants are well characterized, and increased cancer risk associated with these variations is plausible.
A considerable amount of work has been done on these genes in relation to risk for HNC. One of the major problems of these studies is that many have a small sample size (<100 cases or <100 controls). Case-control studies with small sample size are reported to inflate ORs (232) . To clarify the effect of genes on the risk of HNC, meta-analysis is useful because it is a statistical method to integrate and analyze previous research results. Therefore, the results of meta-analyses carry greater significance than the results of individual studies. At present, 23 studies describing metaanalyses of relations between genetic polymorphisms and risk of HNC have been published (232) (233) (234) . The genetic polymorphisms examined were those in the GSTM1, GSTT1, GSTP1, XRCC1 codons 194 and 399, and CYP1A1 codon 462. Among these polymorphisms, a significant relation was observed between the GSTM1-null genotype and increased risk for HNC (Table II) . When the studies on GSTM1 were stratified as to Asians and Caucasians, the risk of HNC was more pronounced in Asian than in Caucasian populations (233) . Polymorphisms in other genes, including GSTT1, GSTP1, Table V . Studies on polymorphisms of folate metabolic enzymes and risk of head and neck cancer. -
XRCC1 (codon 399), and CYP1A1 (codon 462), tend to be associated with an increased risk for HNC. One possible explanation for the lack of significant interaction is that gene-environment interactions are heterogeneous by ethnicity, in which case, pooling data from different ethnicities would dilute the interaction. Another possible explanation is that these gene-environment interactions are heterogeneous by tumor site. For instance, oral cancers may have different genetic backgrounds from those of laryngeal cancers. In addition, the genotype frequencies in controls vary among populations. In the Indian population, the prevalence of the GSTM1-and GSTT1-null genotypes is particularly low. It Table VI . Studies on polymorphisms of extracellular matrix degradation enzymes and risk of head and neck cancer. - Table VII . Studies on polymorphisms of apoptosis signaling factors and risk of head and neck cancer. 
OC, oral cavity; P, pharynx; L, larynx. b OR, odds ratio; 95% CI, 95% confidence interval; c OR and 95% CI were calculated from the genotype distribution.
- Table VIII . Studies on polymorphisms of immune response factors and risk of head and neck cancer. - Table IX . Studies on polymorphisms of growth factors, vitamin and sex hormone, and risk of head and neck cancer. -
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a OC, oral cavity; P, pharynx; L, larynx. b OR, odds ratio; 95% CI, 95% confidence interval. c OR and 95% CI were calculated from the genotype distribution. d Male.
-----------------------------------------------------------------------------------------------------will be of interest to explore further whether these genotypes are more relevant in specific ethnic groups with respect to the risk for HNC. Additional data have been published since the last meta-analysis, and a meta-analysis that includes the most recent data should be conducted to clarify the role of these polymorphisms. Alcohol consumption is a major risk factor for HNC as well as esophageal cancer, and dose-response trends have been reported (6) . There are consistent findings that the *1/*2 genotype of ALDH2 is associated with increased risk of HNC. In contrast, the *2/*2 genotype of the gene might be associated with decreased risk of HNC. The latter finding may seem somewhat confusing. A meta-analysis showed that the *1/*2 genotype of ALDH2 is associated with increased risk and that the *2/*2 genotype is associated with a decreased risk of esophageal cancer (265) . These findings may be due to markedly lower alcohol consumption in *2/*2 vs. *1/*1 homozygotes because *2/*2 homozygotes are alcohol intolerant and can have severe reactions following intake of small amounts of alcohol (250, 265) . Reduced consumption of alcohol may reduce the risk for HNC as well as the risk for esophageal cancer.
ADH2 influences serum concentrations of acetaldehyde after ingestion of alcohol. There has been only 1 study of the relation between ADH2 polymorphisms and HNC risk. ADH2*1/*1 homozygotes shows significantly increased risk for HNC (118) . ADH2*1/*1 homozygotes also show a significantly increased risk for esophageal cancer (10) . Because HNC and esophageal cancer have similar etiologies, ADH2*1*1 homozygotes may have increased risk for both HNC and esophageal cancer. To confirm this hypothesis, further studies needed to confirm the relation between ADH2 polymorphisms and risk for HNC.
There have been consistent findings that the Tyr/His and His/His genotypes of EPHX1 codon 113 are associated with increased risk of HNC. However, results for the relation between EPHX1 codon 139 polymorphisms and risk of HNC are inconsistent. These results may be due to differences in activity between the EPHX1 His113 variant and EPHX1 Arg139 variant.
In addition to ALDH2 and EPHX1 codon 113, there are consistent findings that the p53 codon 72 Pro/Pro genotype is associated with increased HNC risk. Several researchers reported significant associations between the p53 codon 72 Pro/Pro genotype and lung (266) , esophageal (10), gastric (2667) and skin (268) cancers. To confirm the degree to which the p53 codon 72 polymorphism contributes to HNC, meta-analyses should be conducted.
We previously published a review of genetic polymorphisms and risk of esophageal cancer (10) . HNC and esophageal cancer have similar etiologies, and the association between HNC and esophageal cancer is well known (269, 270) . For instance, in a median 29-month follow-up period, esophageal cancer was diagnosed in 7.4% of patients with HNC (269) . Similar patterns of genetic polymorphisms between HNC and esophageal cancer risks are observed. The Val allele of CYP1A1 codon 462, Pro/Pro genotype of p53 codon 72 and the *1/*2 genotype of ALDH2 may increase both risks for HNC and esophageal cancer. However, the GSTM1-null genotype significantly increases the risk of HNC compared with GSTM1-postive genotype, but it does not increase the risk of esophageal cancer (OR, 1.07; 95% CI, 0.76-1.51) according to the results of meta-analyses (232, 233, 265) . Similarly, the GSTT1-null genotype may increase the risk of HNC (OR, 1.17; 95% CI, 0.98-1.40) compared with GSTT1-positive genotype, but it does not increase the risk of esophageal cancer (OR, 0.99; 95% CI, 0.80-1.22) (232, 265) . In contrast to HNC, the occurrence of esophageal cancer shows a remarkable geographic bias. Most patients with esophageal cancer live in the 'esophageal cancer belt', which stretches from North-Central China westward through Central Asia to Northern Iran. Environmental risk factor(s) other than tobacco smoking, alcohol consumption and betel quid chewing may affect the geographic bias, and differences in genetic polymorphisms may also affect the bias.
Most genetic association studies use a case-control design. One important factor is the number of cases available to study. There are some advantages to increasing the number of control subjects (that is, having >1 matched control for each case). In practice 2:1 matching of control subjects to cases often provides the most efficient design for relatively common diseases. The size of the population required to determine a relative risk of a polymorphism is dependent on the allele frequency of the polymorphism. For example, with 90% power, Table X. Summary of previous meta-analyses of genetic polymorphisms and head and neck cancer risk. - -
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a OR, odds ratio; 95% CI, 95% confidence interval.
- The best scientific evidence for associations of genetic factors with risk for HNC will come from large cohort studies that consider simultaneously the different factors potentially involved in carcinogenesis of the head and neck, including genetic polymorphisms and environmental factors, such as drinking alcohol and smoking tobacco. Identification of genetic factors that modify the impacts of environmental factors will depend on direct exploration of interactions between genes and environment (274) . Furthermore, simultaneous analysis of multiple polymorphic genes should be done to address the possibility of identifying gene-gene interactions. The results of such studies will allow us to estimate the relative contribution of individual genetic variations to overall HNC risk.
